AIP
ADCT icon

Ameritas Investment Partners’s ADC Therapeutics ADCT Stock Holding History

Ameritas Investment Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34K Hold
6,859
– – ﹤0.01% 3057
2026
Q1 		$25.7K Hold
6,859
– – ﹤0.01% 2479
2025
Q4 		$24.2K Hold
6,859
– – ﹤0.01% 2545
2025
Q3 		$27.4K Hold
6,859
– – ﹤0.01% 2528
2025
Q2 		$18.4K Hold
6,859
– – ﹤0.01% 2698
2025
Q1 		$9.67K Hold
6,859
– – ﹤0.01% 2833
2024
Q4 		$13.6K Hold
6,859
– – ﹤0.01% 2800
2024
Q3 		$21.6K Hold
6,859
– – ﹤0.01% 2615
2024
Q2 		$21.7K Buy
+6,859
New +$27.3K ﹤0.01% 2577

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameritas Investment Partners's ADCT Position: Q2 2026 in Review

Ameritas Investment Partners held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 6,859 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

Ameritas Investment Partners first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $27.4K in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Ameritas Investment Partners held 6,859 shares of ADC Therapeutics worth $7.34K as of Q2 2026.
  • Ameritas Investment Partners left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #3057 holding.
  • Ameritas Investment Partners first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Ameritas Investment Partners's ADC Therapeutics position peaked at $27.4K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.